Complessivamente, l’analisi della nostra casistica di pazienti consente di confermare l’utilità del trattamento con Rituximab e Micofenolato Mofetile nella
Polidermatomiosite, sebbene vi sia una limitazione nella natura in gran parte
retrospettiva dello studio e non sia stato possibile ottenere dati statisticamente
significativi, data la considerevole differenza numerica dei due campioni.
Sono necessari ulteriori studi su casistiche più ampie e omogenee per individuare
eventuali sottogruppi di pazienti candidabili al trattamento con Rituximab o
Micofenolato Mofetile.
L’importanza sempre maggiore della analisi degli anticorpi miosite specifici (MSA)e miosite associati (MAA) è legata alla speranza di affinare la terapia immunomodulante
già in uso, intervenendo in modo più specifico sui diversi fenotipi di malattia tramite un
78
Bibliografia
1. Miller ML, Vleugels RA. Clinical manifestations of dermatomyositis and polymyositis in adults. In: Ramirez Curtis M, Ofori AO, eds. UptoDate; 2017.
2. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet (London, England) 2003; 362(9388): 971-82.
3. Doria A, Gambari PF. Connettiviti o malattie reumatiche sistemiche. In: Todesco S, Gambari PF, eds. Malattie reumatiche: McGraw-Hill Companies; 2002: 219-326.
4. Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Current opinion in pharmacology 2010; 10(3): 346-52.
5. Dalakas MC. Pathophysiology of inflammatory and autoimmune myopathies. Presse medicale (Paris, France : 1983) 2011; 40(4 Pt 2): e237-47.
6. Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clinical and experimental rheumatology 1999; 17(5): 615-20.
7. Guillet G, Geniaux M. Dermatomiosite. In: Saurat JH, Grosshans E, Laugier P, Lachapelle JM, eds. Dermatologia e malattie sessualmente trasmesse. Milano: Masson; 2006: 389-95. 8. Neri R, Barsotti S, Iacopetti V, et al. Clinically amyopathic dermatomyositis: analysis of a monocentric cohort. Journal of clinical neuromuscular disease 2014; 15(4): 157-60.
9. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991; 70(6): 360-74.
10. Tieu J, Lundberg IE, Limaye V. Idiopathic inflammatory myositis. Best practice & research Clinical rheumatology 2016; 30(1): 149-68.
11. Reed AM, Ytterberg SR. Genetic and environmental risk factors for idiopathic
inflammatory myopathies. Rheumatic diseases clinics of North America 2002; 28(4): 891-916. 12. Morgan OS, Rodgers-Johnson P, Mora C, Char G. HTLV-1 and polymyositis in Jamaica. Lancet (London, England) 1989; 2(8673): 1184-7.
13. Dalakas MC, Karpati G. The inflammatory myopathies. Disorders of Voluntary Muscle 2010: 427-52.
14. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. Journal of Clinical Investigation 1994; 94(5): 1729-35.
15. Schmidt J, Dalakas MC. Pathomechanisms of inflammatory myopathies: Recent advances and implications for diagnosis and therapies. Expert Opinion on Medical Diagnostics 2010; 4(3): 241-50.
16. Dalakas MC. Review: An update on inflammatory and autoimmune myopathies. Neuropathology and applied neurobiology 2011; 37(3): 226-42.
17. Walsh RJ, Sek WK, Yao Y, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis and rheumatism 2007; 56(11): 3784-92.
18. Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007; 69(21): 2008-19.
19. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008; 70(6): 418-24.
20. Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977; 56(4): 255-86.
79
22. Wright NA, Vleugels RA, Callen JP. Cutaneous dermatomyositis in the era of biologicals. Seminars in immunopathology 2016; 38(1): 113-21.
23. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. The New England journal of medicine 1991; 325(21): 1487-98.
24. Dugan EM, Huber AM, Miller FW, Rider LG, International Myositis A, Clinical Studies G. Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatology online journal 2009; 15(2): 1.
25. Muro Y, Sugiura K, Akiyama M. Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features-a Comprehensive Review. Clinical reviews in allergy & immunology 2016; 51(3): 293-302.
26. Cao H, Pan M, Kang Y, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma
differentiation-associated gene 5 antibody. Arthritis care & research 2012; 64(10): 1602-10. 27. Walsh JS, Fairley JA. Calcifying disorders of the skin. Journal of the American Academy of Dermatology 1995; 33(5 Pt 1): 693-706; quiz 7-10.
28. Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clinical and experimental rheumatology 1996; 14(3): 263-74.
29. Hochberg MC, Feldman D, Stevens MB, Arnett FC, Reichlin M. Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. The Journal of rheumatology 1984; 11(5): 663-5.
30. Marie I, Menard JF, Hachulla E, et al. Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Seminars in arthritis and rheumatism 2011; 41(1): 48-60.
31. Lundberg IE. The heart in dermatomyositis and polymyositis. Rheumatology (Oxford, England) 2006; 45 Suppl 4: iv18-21.
32. Denbow CE, Lie JT, Tancredi RG, Bunch TW. Cardiac involvement in polymyositis: a clinicopathologic study of 20 autopsied patients. Arthritis and rheumatism 1979; 22(10): 1088- 92.
33. Tisseverasinghe A, Bernatsky S, Pineau CA. Arterial events in persons with dermatomyositis and polymyositis. The Journal of rheumatology 2009; 36(9): 1943-6. 34. Lin YN, Lin CL, Chang KC, Kao CH. Increased subsequent risk of acute coronary syndrome for patients with dermatomyositis/polymyositis: a nationwide population-based retrospective cohort study. Scandinavian journal of rheumatology 2015; 44(1): 42-7.
35. Rai SK, Choi HK, Sayre EC, Avina-Zubieta JA. Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study. Rheumatology (Oxford, England) 2016; 55(3): 461-9.
36. Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine 2004; 83(1): 35-42.
37. Huber AM. Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment. Paediatric drugs 2009; 11(6): 361-74.
38. Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. Journal of neurology, neurosurgery, and psychiatry 2009; 80(10): 1060-8.
39. Neri R, Barsotti S, Iacopetti V, et al. Cancer-associated myositis: a 35-year retrospective study of a monocentric cohort. Rheumatology international 2014; 34(4): 565-9.
40. Barnes BE, Mawr B. Dermatomyositis and malignancy. A review of the literature. Annals of internal medicine 1976; 84(1): 68-76.
41. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. The New England journal of medicine 1992; 326(6): 363-7.
80
42. Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-
associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis and rheumatism 2013; 65(11): 2954-62.
43. Albert ML, Darnell RB. Paraneoplastic neurological degenerations: keys to tumour immunity. Nature reviews Cancer 2004; 4(1): 36-44.
44. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in
dermatomyositis and polymyositis: a population-based study. Lancet (London, England) 2001; 357(9250): 96-100.
45. Bivalacqua TJ, Alphs H, Aksentijevich I, Schaeffer EM, Schoenberg MP. Paraneoplastic polyarthritis from non-small-cell lung cancer metastatic to the bladder. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25(18): 2621-3. 46. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis and rheumatism 2006; 54(11): 3682-9.
47. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Annals of the rheumatic diseases 2007; 66(10): 1345-9.
48. Dalakas MC. Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology 2006; 66(2 SUPPL. 1): S33-S8.
49. Kagen LJ. Myoglobinemia and myoglobinuria in patients with myositis. Arthritis and rheumatism 1971; 14(4): 457-64.
50. Targoff IN. Autoantibodies and their significance in myositis. Current rheumatology reports 2008; 10(4): 333-40.
51. Bizzaro N, Wiik A. Appropriateness in anti-nuclear antibody testing: from clinical request to strategic laboratory practice. Clinical and experimental rheumatology 2004; 22(3): 349-55.
52. Bossuyt X, Hendrickx A, Frans J. Antinuclear antibody titer and antibodies to extractable nuclear antigens. Arthritis and rheumatism 2005; 53(6): 987-8.
53. Brouwer R, Hengstman GJ, Vree Egberts W, et al. Autoantibody profiles in the sera of European patients with myositis. Annals of the rheumatic diseases 2001; 60(2): 116-23. 54. Ghirardello A, Zampieri S, Iaccarino L, et al. [Myositis specific and myositis associated autoantibodies in idiopathic inflammatory myopathies: a serologic study of 46 patients]. Reumatismo 2005; 57(1): 22-8.
55. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford, England) 2009; 48(6): 607-12.
56. Plotz PH, Rider LG, Targoff IN, Raben N, O'Hanlon TP, Miller FW. NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Annals of internal medicine 1995; 122(9): 715-24.
57. Milone M. Diagnosis and Management of Immune-Mediated Myopathies. Mayo Clinic proceedings 2017; 92(5): 826-37.
58. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle
autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis and rheumatism 2004; 50(1): 209-15.
59. Reeves WH, Nigam SK, Blobel G. Human autoantibodies reactive with the signal- recognition particle. Proc Natl Acad Sci U S A 1986; 83(24): 9507-11.
60. Miller T, Al-Lozi M, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: Clinical and pathological features. Journal of Neurology Neurosurgery and Psychiatry 2002; 73(4): 420-8.
61. Dobloug C, Garen T, Bitter H, et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Annals of the rheumatic diseases 2015; 74(8): 1551-6.
81
62. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis and rheumatism 1990; 33(9): 1361-70.
63. Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Annals of the rheumatic diseases 2006; 65(12): 1635-8.
64. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. Journal of neurology, neurosurgery, and psychiatry 2002; 73(4): 420-8.
65. Shamim EA, Rider LG, Pandey JP, et al. Differences in idiopathic inflammatory
myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis and rheumatism 2002; 46(7): 1885-93.
66. Betteridge ZE, Gunawardena H, Chinoy H, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Annals of the rheumatic diseases 2009; 68(10): 1621-5.
67. Mandel DE, Malemud CJ, Askari AD. Idiopathic Inflammatory Myopathies: A Review of the Classification and Impact of Pathogenesis. International journal of molecular sciences 2017; 18(5).
68. Barsotti S, Zampa V, Talarico R, et al. Thigh magnetic resonance imaging for the
evaluation of disease activity in patients with idiopathic inflammatory myopathies followed in a single center. Muscle & nerve 2016; 54(4): 666-72.
69. Day J, Patel S, Limaye V. The role of magnetic resonance imaging techniques in evaluation and management of the idiopathic inflammatory myopathies. Seminars in arthritis and rheumatism 2017; 46(5): 642-9.
70. Saurat JH, Grosshans E, Laugier P, Lachapelle JM. Dermatologia e malattie sessualmente trasmesse. Milano: Masson; 2006.
71. Dalakas MC. Muscle biopsy findings in inflammatory myopathies. Rheumatic diseases clinics of North America 2002; 28(4): 779-98, vi.
72. Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology,
classification, and diagnostic criteria. Rheumatic diseases clinics of North America 2002; 28(4): 723-41.
73. Moghadam-Kia S, Aggarwal R, Oddis CV. Treatment of inflammatory myopathy:
emerging therapies and therapeutic targets. Expert review of clinical immunology 2015; 11(11): 1265-75.
74. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel
classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 2005; 84(4): 231-49. 75. Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. The American journal of medicine 1993; 94(4): 379-87. 76. Bolosiu HD, Man L, Rednic S. The effect of methylprednisolone pulse therapy in
polymyositis/dermatomyositis. Advances in experimental medicine and biology 1999; 455: 349- 57.
77. Aggarwal R, Oddis CV. Therapeutic approaches in myositis. Current rheumatology reports 2011; 13(3): 182-91.
78. Cagnoli M, Marchesoni A, Tosi S. Combined steroid, methotrexate and chlorambucil therapy for steroid-resistant dermatomyositis. Clinical and experimental rheumatology 1991; 9(6): 658-9.
79. Marie I, Hachulla E, Cherin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis and rheumatism 2002; 47(6): 614-22.
82
80. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. American journal of respiratory and critical care medicine 2001; 164(7): 1182-5.
81. Aggarwal R, Oddis CV, Goudeau D, et al. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology (Oxford, England) 2016; 55(6): 991-9.
82. Aggarwal R, Oddis CV. Therapeutic advances in myositis. Current opinion in rheumatology 2012; 24(6): 635-41.
83. Iorizzo LJ, 3rd, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. Journal of the American Academy of Dermatology 2008; 59(1): 99-112.
84. Lueck CJ, Trend P, Swash M. Cyclosporin in the management of polymyositis and dermatomyositis. Journal of neurology, neurosurgery, and psychiatry 1991; 54(11): 1007-8. 85. Keen RW, Gumpel JM. Cyclosporin A in adult dermatomyositis. British journal of rheumatology 1993; 32(5): 439.
86. Zabel P, Leimenstoll G, Gross WL. Cyclosporin for acute dermatomyositis. Lancet (London, England) 1984; 1(8372): 343.
87. Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. Journal of the American Academy of Dermatology 1984; 10(4): 592-600.
88. Marie I. Therapy of polymyositis and dermatomyositis. Presse medicale (Paris, France : 1983) 2011; 40(4 Pt 2): e257-70.
89. Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of
intravenous immunoglobulin in treatment of neurological diseases. European journal of neurology 2008; 15(9): 893-908.
90. Siberil S, Elluru S, Negi VS, et al. Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2007; 37(1): 103-7.
91. Danieli MG, Calcabrini L, Calabrese V, Marchetti A, Logullo F, Gabrielli A. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmunity reviews 2009; 9(2): 124-7.
92. Danieli MG, Pettinari L, Moretti R, Logullo F, Gabrielli A. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmunity reviews 2011; 10(3): 144-9.
93. Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Archives of dermatology 2006; 142(1): 65-9.
94. Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of the inflammatory myopathies: update and practical recommendations. Expert opinion on pharmacotherapy 2009; 10(7): 1183-90.
95. Shinjo SK, de Souza FH, de Moraes JC. Dermatomyositis and polymyositis: from immunopathology to immunotherapy (immunobiologics). Revista brasileira de reumatologia 2013; 53(1): 101-10.
96. Schioppo T, Ingegnoli F. Current perspective on rituximab in rheumatic diseases. Drug design, development and therapy 2017; 11: 2891-904.
97. Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford, England) 2017; 56(2): 247-54.
98. Fasano S, Gordon P, Hajji R, Loyo E, Isenberg DA. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology (Oxford, England) 2017; 56(1): 26-36.
83
99. Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. The Journal of biological chemistry 1995; 270(21): 12398-403.
100. Frieling U, Luger TA. Mycophenolate mofetil and leflunomide: promising compounds for the treatment of skin diseases. Clinical and experimental dermatology 2002; 27(7): 562-70. 101. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis and rheumatism 2004; 50(6): 1939-50.
102. Tlacuilo-Parra JA, Guevara-Gutierrez E, Rodriguez-Castellanos MA, Ornelas-Aguirre JM, Barba-Gomez JF, Salazar-Paramo M. Leflunomide in the treatment of psoriasis: results of a phase II open trial. The British journal of dermatology 2004; 150(5): 970-6.
103. Schmitt J, Wozel G, Pfeiffer C. Leflunomide as a novel treatment option in severe atopic dermatitis. The British journal of dermatology 2004; 150(6): 1182-5.
104. Majithia V, Sanders S, Harisdangkul V, Wilson JG. Successful treatment of sarcoidosis with leflunomide. Rheumatology (Oxford, England) 2003; 42(5): 700-2.
105. Nousari HC, Anhalt GJ. Bullous pemphigoid treated with leflunomide: a novel immunomodulatory agent. Archives of dermatology 2000; 136(10): 1204-5.
106. Fafalak RG, Peterson MG, Kagen LJ. Strength in polymyositis and dermatomyositis: best outcome in patients treated early. The Journal of rheumatology 1994; 21(4): 643-8.
107. Carpenter JR, Bunch TW, Engel AG, O'Brien PC. Survival in polymyositis: corticosteroids and risk factors. The Journal of rheumatology 1977; 4(2): 207-14.
108. Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis and rheumatism 1985; 28(7): 796-803.
109. Casciola-Rosen L, Mammen AL. Myositis autoantibodies. Current opinion in rheumatology 2012; 24(6): 602-8.
110. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis and rheumatism 2013; 65(2): 314-24.
111. Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 2006; 66(8): 1245-7.
112. Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford, England) 2005; 44(3): 386-9. 113. Schneider C, Gold R, Schafers M, Toyka KV. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle & nerve 2002; 25(2): 286-8. 114. Pisoni CN, Cuadrado MJ, Khamashta MA, Hughes GR, D'Cruz DP. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford, England) 2007; 46(3): 516-8. 115. Bandelier C, Guerne PA, Genevay S, Finckh A, Gabay C. Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies. Swiss medical weekly 2009; 139(3-4): 41-6.
84 RINGRAZIAMENTI
A conclusione di questo mio percorso universitario, che è stato per me particolarmente
difficile, sono grata di provare due tipi di felicità: quella che deriva dagli altri e quella
che deriva dai propri sforzi.
Ringrazio la mia famiglia, tutta la mia inusuale famiglia. Ringrazio mia madre, per
avermi sempre aiutata nei momenti difficili, sostenuta nella realizzazione di questo mio sogno, di aver sempre creduto in me anche quando sembrava che non ce l’avrei fatta; mi hai insegnato il valore dell’umiltà, che perdonare a volte è facile perché è necessario e a non serbare mai rancore, verso nessuno.
Ringrazio mio padre, sia per il supporto che mi ha sempre dato, sia, soprattutto, per